LINC02312: A Drug Target / Disease Biomarker (G100132612)

Target Name: LINC02312

NCBI ID: G100132612

LINC02312

Other Name(s): Long intergenic non-protein coding RNA 2312 | long intergenic non-protein coding RNA 2312

LINC02312: A Drug Target / Disease Biomarker

LINC02312 is a protein that is expressed in various tissues of the body, including the brain, heart, and kidneys. It is a member of the LINC family of proteins, which are known for their role in regulating gene expression and cell-cell signaling. LINC02312 has been shown to play a role in the regulation of stem cell proliferation and the development of cancer.

One of the most promising aspects of LINC02312 is its potential as a drug target. LINC02312 has been shown to interact with a variety of molecules, including the oncogene PDGF-BB and the tumor suppressor gene p53. This suggests that LINC02312 could be a useful target for the treatment of cancer.

In addition to its potential as a drug target, LINC02312 has also been shown to be a valuable biomarker for the diagnosis and prognosis of cancer. LINC02312 has been shown to be expressed in various types of cancer, including breast, lung, and ovarian cancer. Additionally, studies have shown that LINC02312 levels can be used as a predictor of cancer outcomes, including cancer recurrence and survival.

The identification of a potential drug target for LINC02312 is an exciting step in the development of new treatments for cancer. LINC02312 is a promising target because it is involved in the regulation of important processes that are involved in cancer development, and because it has been shown to interact with a variety of molecules that are involved in cancer treatment. Further research is needed to determine the full potential of LINC02312 as a drug target and biomarker for cancer.

Protein Name: Long Intergenic Non-protein Coding RNA 2312

The "LINC02312 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC02312 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets